Developer docs
API playgroundTry for free, no card

Search company profiles

GSK Canada

Full company profile

uuid000ems8

Namestring
GSK Canada
Legal namestring
GlaxoSmithKline Inc.
Websiteurl
ca.gsk.com
Company typeenum
Private
Founded yearint
1902
Descriptiontext

GSK Canada (legal entity GlaxoSmithKline Inc.) is the wholly-owned Canadian operating subsidiary of UK-listed GSK plc, headquartered in Mississauga, Ontario with divisional offices in Montréal and Québec City and a Ste-Foy vaccine manufacturing facility. The company operates as a research-based biopharmaceutical business employing approximately 1,629 full-time staff across Canada and reporting FY2024 sales of approximately $1.05 billion. Its portfolio spans three categories: specialty medicines (oncology assets Blenrep, Jemperli, Ojjaara, Zejula; immunology/respiratory biologics Benlysta, Nucala, Exdensur), vaccines (Shingrix, Arexvy, Bexsero, Boostrix, Cervarix, FluLaval Tetra, and others), and general medicines (Advair, Trelegy Ellipta, Ventolin, Valtrex, plus the Stiefel dermatology line). The company also operates ViiV Healthcare in Canada as a majority-owned HIV-focused subsidiary with Pfizer and Shionogi as minority shareholders.

The underlying technology base rests on proprietary adjuvant systems (AS01E/AS01B used in Shingrix and Arexvy), the ELLIPTA dry powder inhaler platform across multiple respiratory brands, and an R&D approach that combines human genetics, functional genomics, AI/ML, and the Microsoft Discovery agentic AI platform to identify drug targets and design new molecules across respiratory, immunology, oncology, HIV, and infectious diseases. Manufacturing is anchored by the Ste-Foy facility, which produces a significant share of Canada's seasonal influenza vaccine supply and serves as the domestic source for pandemic influenza vaccine requirements.

GSK Canada generates revenue through prescription pharmaceutical product sales reimbursed via a hybrid of public channels (pCPA pan-Canadian negotiations, provincial formularies such as RAMQ in Quebec), private payers, and dedicated patient support programs (MyMoment, Vista, Monarch, Jemperli, Horizon, Zejula). The go-to-market combines enterprise field sales to healthcare professionals, HCP self-serve portals (GSKPro, GSK Medical), pharmacy network partnerships (Innovicares, Valtrex One), and direct distribution through wholesalers and the Ste-Foy manufacturing site. Customers include physicians, specialists, hospitals, pharmacists, and provincial health authorities, with patient advocacy organizations funded through grants as part of stakeholder engagement.

Short descriptiontext

GSK Canada is the wholly-owned Canadian subsidiary of GSK plc, selling specialty medicines, vaccines, and general medicines across oncology, respiratory, HIV, and infectious diseases, generating approximately $1.05 billion in 2024 revenue through prescription and public reimbursement channels.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
prescription pharmaceuticals, vaccine manufacturing, specialty medicines, respiratory therapeutics, oncology biologics
Industry1 code
PRIMARYHLAIAEAE
Travel & Tropical Disease Vaccines
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales (Vaccines, Specialty Medicines, General Medicines)
TypeHardware Sales
Description

Primary revenue from sales of prescription medicines, vaccines, and consumer health products across Canada. 2024 GSK in Canada Sales: $1,054,949,000. Total Payments to HCPs and HCOs represent 2.03% of Sales.

ca.gsk.com
2Specialty Medicines Sales
TypeHardware Sales
Description

Revenue from specialty medicines including oncology products (Blenrep, Jemperli, Ojjaara, Zejula), immunology/respiratory products (Benlysta, Nucala, Exdensur), and Flolan.

ca.gsk.com
3Vaccine Sales
TypeHardware Sales
Description

Revenue from vaccines including Shingrix, Arexvy (RSV), Boostrix, Bexsero, Cervarix, Engerix-B, FluLaval Tetra, Havrix, Infanrix-Hexa, Menjugate Liquid, Menveo, Priorix, Rotarix, Synflorix, Twinrix, Varilrix, Arepanrix H5N1, Flulaval Tetra, Fluviral, Priorix-Tetra.

ca.gsk.com
4General Medicines Sales
TypeHardware Sales
Description

Revenue from general medicines including Advair, Anoro Ellipta, Arnuity Ellipta, Avamys, Avodart, Breo Ellipta, Clavulin, Flolan, Flovent, Imitrex, Incruse Ellipta, Jalyn, Lamictal, Malarone, Mepron, Parnate, Paxil, Relenza, Serevent, Trelegy Ellipta, Valtrex, Ventolin, Volibris, and Stiefel dermatology products (Clindoxyl, Stieprox, Stieva-A).

ca.gsk.com
Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
12024 GSK in Canada Sales of $1,054,949,000 with HCP/HCO payments representing 2.03% of Sales
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing for individual products is not publicly disclosed; products are sold through prescription and reimbursement channels. Aggregate payments to HCPs: $5,147,647.42; aggregate payments to HCOs: $16,298,250.00 in 2024.

ca.gsk.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Stiefel
Description

A world-leading specialist dermatology business with innovative products, described as 'Stiefel, a GSK company', offering products like CLINDOXYL, STIEPROX, and STIEVA-A in Canada.

ca.gsk.com
+1 more record
Core offering1 text field

GSK Canada researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines in Canada across three product pillars: Specialty Medicines (oncology and immunology/respiratory biologics such as Blenrep, Jemperli, Ojjaara, Zejula, Benlysta, Nucala, Exdensur), Vaccines (including adjuvanted vaccines Shingrix and Arexvy, plus paediatric and adult immunizations), and General Medicines (respiratory, dermatology, anti-infective and primary care products including the Ellipta inhaler family, Ventolin, Advair, Valtrex, Malarone, Paxil, and Stiefel dermatology brands). The company supports access via patient support programs, public reimbursement negotiations, and HCP-focused portals, and operates the Ste-Foy Vaccine Production Facility in Quebec that supplies Canada's seasonal and pandemic influenza vaccines.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

GSK Canada's portfolio is organized across three product categories: Specialty medicines, Vaccines, and General medicines. The Specialty medicines portfolio focuses on oncology and respiratory/immunology, including BLENREP (multiple myeloma), JEMPERLI (endometrial cancer), OJJAARA (myelofibrosis), ZEJULA (ovarian cancer), BENLYSTA (lupus), EXDENSUR (severe asthma), and NUCALA (COPD/severe asthma). The Vaccines portfolio is one of the broadest in the industry and includes SHINGRIX (shingles), AREXVY (RSV), BEXSERO (meningococcal B), BOOSTRIX (Tdap), CERVARIX (HPV), ENGERIX-B, HAVRIX, MENVEO, PRIORIX (MMR), TWINRIX (Hep A/B), VARILRIX, FLULAVAL Tetra, and pediatric vaccines. The General medicines portfolio covers respiratory therapies (ADVAIR, ANORO ELLIPTA, BREO ELLIPTA, FLOVENT, INCRUSE ELLIPTA, SEREVENT, TRELEGY ELLIPTA, VENTOLIN), anti-infectives (CLAVULIN, MALARONE, VALTREX), and additional treatments. The Stiefel Dermatology line (CLINDOXYL, STIEPROX, STIEVA-A) adds specialized dermatology products. GSK Canada's R&D is supported by a Ste-Foy vaccine manufacturing facility in Québec that produces Canada's seasonal influenza vaccine and pandemic influenza vaccine requirements.

Product and service29 records
1BENLYSTA (belimumab)
CategorySpecialty medicine (Immunology)
Description

A specialty biologic medicine for the treatment of systemic lupus erythematosus (lupus), targeting B-lymphocyte stimulator (BLyS). Supported by the Monarch Patient Support Program.

2BLENREP (belantamab mafodotin)
CategorySpecialty medicine (Oncology)
Description

An antibody-drug conjugate approved in Canada as combination therapy for relapsed/refractory multiple myeloma. Supported by the MyMoment Patient Support Program. pCPA negotiations initiated May 2026.

3EXDENSUR (depemokimab)
CategorySpecialty medicine (Respiratory)
Description

A long-acting anti-IL-5 monoclonal antibody approved by Health Canada on June 16, 2026 for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps.

4JEMPERLI (dostarlimab)
CategorySpecialty medicine (Oncology)
Description

A PD-1 inhibitor (anti-PD-1 monoclonal antibody) approved for primary advanced or first recurrent endometrial cancer in combination with chemotherapy. Supported by the Jemperli Patient Support Program. Quebec RAMQ public reimbursement effective February 2026.

5NUCALA (mepolizumab)
CategorySpecialty medicine (Respiratory)
Description

An anti-IL-5 monoclonal antibody approved by Health Canada on June 9, 2026 as add-on maintenance treatment for adult patients with COPD, in addition to severe asthma and other indications. Supported by the Vista Patient Support Program.

6OJJAARA (momelotinib)
CategorySpecialty medicine (Oncology)
Description

A JAK1/JAK2/ACVR1 inhibitor approved for myelofibrosis in adults with moderate to severe anemia. First publicly reimbursed in Quebec via RAMQ in November 2025. Supported by the MyMoment Patient Support Program.

7ZEJULA (niraparib)
CategorySpecialty medicine (Oncology)
Description

A PARP inhibitor for the maintenance treatment of ovarian cancer. Supported by the Zejula Patient Support Program.

8SHINGRIX (Recombinant, AS01B adjuvanted)
CategoryVaccine (Infectious diseases)
Description

Herpes Zoster (shingles) vaccine, non-live recombinant and AS01B adjuvanted, for adults 50 years and older.

9AREXVY (RSV vaccine, recombinant, AS01E adjuvanted)
CategoryVaccine (Infectious diseases)
Description

Respiratory Syncytial Virus (RSV) vaccine approved for older adults in Canada and publicly funded through prevention programs for older adults as of September 2025.

10BEXSERO
CategoryVaccine (Infectious diseases)
Description

Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) for protection against meningococcal group B disease.

11BOOSTRIX
CategoryVaccine (Infectious diseases)
Description

Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine for booster vaccination (Tdap), also available as BOOSTRIX-Polio with inactivated poliomyelitis component.

12CERVARIX
CategoryVaccine (Infectious diseases)
Description

Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) for cervical cancer prevention.

13ENGERIX-B
CategoryVaccine (Infectious diseases)
Description

Hepatitis B surface antigen (recombinant) vaccine for hepatitis B prevention.

14FLULAVAL Tetra
CategoryVaccine (Infectious diseases)
Description

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) for seasonal influenza prevention. Shipped annually by GSK Canada from the Ste-Foy manufacturing facility.

15HAVRIX
CategoryVaccine (Infectious diseases)
Description

Hepatitis A virus, inactivated vaccine for hepatitis A prevention.

16MENVEO
CategoryVaccine (Infectious diseases)
Description

Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine for meningococcal disease prevention.

17PRIORIX
CategoryVaccine (Infectious diseases)
Description

Combined measles, mumps and rubella vaccine, live, attenuated (MMR). Also available as PRIORIX-Tetra with varicella.

18TWINRIX
CategoryVaccine (Infectious diseases)
Description

Combined hepatitis A virus (inactivated) and hepatitis B surface antigen (recombinant) vaccine.

19VARILRIX
CategoryVaccine (Infectious diseases)
Description

Varicella Virus Vaccine, live, attenuated (Oka-strain) for chickenpox prevention.

20ADVAIR (salmeterol, fluticasone propionate)
CategoryGeneral medicine (Respiratory)
Description

A combination inhaler (ICS/LABA) containing salmeterol and fluticasone propionate for asthma and COPD.

21ANORO ELLIPTA (umeclidinium and vilanterol)
CategoryGeneral medicine (Respiratory)
Description

A long-acting dual bronchodilator (LAMA/LABA) inhaler for the maintenance treatment of COPD, delivered via the Ellipta device.

22BREO ELLIPTA (fluticasone furoate / vilanterol)
CategoryGeneral medicine (Respiratory)
Description

A once-daily ICS/LABA combination inhaler for asthma and COPD maintenance treatment, delivered via the Ellipta device.

23FLOVENT (fluticasone propionate)
CategoryGeneral medicine (Respiratory)
Description

An inhaled corticosteroid for the maintenance treatment of asthma.

24INCRUSE ELLIPTA (umeclidinium)
CategoryGeneral medicine (Respiratory)
Description

A long-acting muscarinic antagonist (LAMA) inhaler for the maintenance treatment of COPD, delivered via the Ellipta device.

25TRELEGY ELLIPTA (fluticasone furoate / umeclidinium / vilanterol)
CategoryGeneral medicine (Respiratory)
Description

The first single-inhaler triple therapy (ICS/LAMA/LABA) for the maintenance treatment of asthma and COPD, delivered via the Ellipta device.

26VENTOLIN (salbutamol sulphate)
CategoryGeneral medicine (Respiratory)
Description

A short-acting beta-agonist (SABA) rescue inhaler for asthma and COPD symptoms, available as Ventolin HFA, Ventolin Diskus, Ventolin Respirator Solution, and Ventolin I.V. Infusion Solution.

27VALTREX (valacyclovir hydrochloride)
CategoryGeneral medicine (Infectious diseases)
Description

An antiviral medication for the treatment of herpes simplex, herpes zoster (shingles), and chickenpox. Supported by the Valtrex One program and Innovicares.

28MALARONE (atovaquone and proguanil hydrochloride)
CategoryGeneral medicine (Infectious diseases)
Description

An antimalarial medication for the prevention and treatment of malaria caused by Plasmodium falciparum.

29Stiefel Dermatology Portfolio (CLINDOXYL, STIEPROX, STIEVA-A)
CategoryStiefel Dermatology (General medicine)
Description

Stiefel (a GSK company) specialty dermatology products including Clindoxyl (clindamycin/benzoyl peroxide) for acne, Stieprox (ciclopirox olamine) for seborrheic dermatitis and dandruff, and Stieva-A (tretinoin) for acne vulgaris.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

Long-standing partnership supporting emergency preparedness for Indigenous children, families and communities at risk of natural disasters. 11,500+ emergency backpacks assembled since 2016 across Alberta, Saskatchewan, Manitoba, Ontario, and Quebec. Aligned with GSK's global partnership with Save the Children.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Ad hoc grants provided to support recovery and relief efforts in response to natural disasters, providing support to communities where GSK employees work and live. Funds are used to provide shelter, essential items and comfort to those impacted.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing supporter; GSK contributed $100,000 in 2025 to help ensure every Canadian has access to quality hospice palliative care. Over $3 million contributed over the last 20 years to support the hospice palliative care movement in Canada.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded to improve access to medicine and healthcare to children and families living in vulnerable communities around the world.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Environmental sustainability partner; supported to reduce carbon emissions from coast to coast in Canada.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

STEM education partner in Canada, supporting equitable education in science, technology, engineering and math for underrepresented populations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

STEM education partner in Canada, supporting equitable education in science, technology, engineering and math.

8Quebec Consortium for Drug Development (CQDM)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Innovation hub partner; GSK Canada works actively with CQDM to investigate new therapeutic targets as well as disruptive platforms for discovery and development.

ca.gsk.com
Strategic tierCoreTypeOthers
Description

Cross-sectoral partner to strengthen and grow the innovation environment in Canada. GSK engages with Innovative Medicines Canada, including adherence to its Code of Ethical Practices and Voluntary Framework on Disclosure of payments to HCPs/HCOs.

10Canadian Health Policy Institute
Strategic tierMinorTypeOthers
Description

Cross-sectoral partner; works with GSK on strengthening the innovation environment in Canada.

ca.gsk.com
11Coalition for Action on Innovation in Canada
Strategic tierMinorTypeOthers
Description

Cross-sectoral partner; works with GSK to strengthen the innovation environment in Canada.

ca.gsk.com
Strategic tierMinorTypeOthers
Description

Cross-sectoral partner; works with GSK to strengthen and grow the innovation environment in Canada.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Negotiation partner for public reimbursement of GSK products in Canada. Successful negotiations completed for Jemperli (Dec 2025) and Ojjaara (Nov 2025); negotiations initiated for Blenrep (May 2026); letter of intent agreed for Ojjaara (Sep 2025).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to address health equity gaps through the GSK Vaccinology and Health Equity Fellowship Award, awarded to Dr. Stephana Julia Moss in June 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

GSK Canada supports the Medications and Sharps Return Programs of HPSA, providing patients with safe and convenient methods to dispose health products in an environmentally responsible way.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

GSK majority-owns ViiV Healthcare (with Pfizer and Shionogi as shareholders); ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV, with an ambition to end the HIV epidemic. Luis Morales serves as General Manager, ViiV Healthcare Canada on GSK Canada's leadership team.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pfizer Canada is a direct peer as a major multinational pharmaceutical subsidiary operating in Canada across vaccines, oncology, and primary care. Both compete for pCPA reimbursement, HCP engagement, and specialty medicine market share.

TypeDirect peer
Description

Merck Canada is a direct peer operating in oncology (Keytruda), vaccines, and specialty medicines in Canada. Both companies compete for hospital and specialty pharmacy channels, pCPA negotiations, and Keytruda directly competes with Jemperli in oncology indications.

3AstraZeneca Canada
TypeDirect peer
Description

AstraZeneca Canada is a direct peer with overlapping respiratory, oncology, and vaccine franchises. Compete head-to-head in COPD/asthma biologics (e.g., Tezspire vs Nucala/Exdensur) and oncology (Imfinzi/Enhertu vs Jemperli/Blenrep).

TypeDirect peer
Description

Novartis Canada is a direct peer with overlapping specialty medicine portfolio including oncology, respiratory, and immunology products. Both participate in pCPA negotiations for high-cost specialty therapeutics and have similar Canadian commercial infrastructure.

TypeDirect peer
Description

Roche Canada is a direct peer in oncology, respiratory, and specialty therapeutics. Compete directly in oncology indications with overlapping HER2/PD-L1 targets and have similar patient support program models for specialty drug access.

TypeDirect peer
Description

Sanofi Canada is a direct peer with a similar portfolio structure (specialty medicines, vaccines including flu/pediatric, and general medicines). Compete directly in vaccines (Sanofi flu vaccines vs Flulaval) and respiratory (Dupixent vs Nucala/Exdensur).

7Bristol-Myers Squibb Canada
TypeDirect peer
Description

Bristol-Myers Squibb Canada is a direct peer in oncology and specialty medicines. Compete with GSK's PD-1 inhibitor (Jemperli) through Opdivo and have overlapping interests in multiple myeloma and hematology indications.

TypeDirect peer
Description

Janssen (J&J Innovative Medicine) Canada is a direct peer in oncology, immunology, and pulmonary hypertension. Compete directly in multiple myeloma (Darzalex vs Blenrep combinations) and immunology (Tremfya vs Benlysta).

9AbbVie Canada
TypeDirect peer
Description

AbbVie Canada is a direct peer in immunology, oncology, and specialty therapeutics. Compete with Benlysta (lupus) through Skyrizi/Rinvoq and have overlapping interests in hematology and specialty pharmacy distribution.

TypeBroad incumbent
Description

Eli Lilly Canada is a broad incumbent peer in pharmaceuticals with an expanding Canadian specialty and primary care portfolio. Compete in diabetes, oncology, and immunology, and participate in pCPA negotiations for high-cost specialty therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GSK Canada

Pharmaceuticalsca.gsk.com

GSK Canada is the wholly-owned Canadian subsidiary of GSK plc, selling specialty medicines, vaccines, and general medicines across oncology, respiratory, HIV, and infectious diseases, generating approximately $1.05 billion in 2024 revenue through prescription and public reimbursement channels.

What GSK Canada does

GSK Canada (legal entity GlaxoSmithKline Inc.) is the wholly-owned Canadian operating subsidiary of UK-listed GSK plc, headquartered in Mississauga, Ontario with divisional offices in Montréal and Québec City and a Ste-Foy vaccine manufacturing facility. The company operates as a research-based biopharmaceutical business employing approximately 1,629 full-time staff across Canada and reporting FY2024 sales of approximately $1.05 billion. Its portfolio spans three categories: specialty medicines (oncology assets Blenrep, Jemperli, Ojjaara, Zejula; immunology/respiratory biologics Benlysta, Nucala, Exdensur), vaccines (Shingrix, Arexvy, Bexsero, Boostrix, Cervarix, FluLaval Tetra, and others), and general medicines (Advair, Trelegy Ellipta, Ventolin, Valtrex, plus the Stiefel dermatology line). The company also operates ViiV Healthcare in Canada as a majority-owned HIV-focused subsidiary with Pfizer and Shionogi as minority shareholders.

The underlying technology base rests on proprietary adjuvant systems (AS01E/AS01B used in Shingrix and Arexvy), the ELLIPTA dry powder inhaler platform across multiple respiratory brands, and an R&D approach that combines human genetics, functional genomics, AI/ML, and the Microsoft Discovery agentic AI platform to identify drug targets and design new molecules across respiratory, immunology, oncology, HIV, and infectious diseases. Manufacturing is anchored by the Ste-Foy facility, which produces a significant share of Canada's seasonal influenza vaccine supply and serves as the domestic source for pandemic influenza vaccine requirements.

GSK Canada generates revenue through prescription pharmaceutical product sales reimbursed via a hybrid of public channels (pCPA pan-Canadian negotiations, provincial formularies such as RAMQ in Quebec), private payers, and dedicated patient support programs (MyMoment, Vista, Monarch, Jemperli, Horizon, Zejula). The go-to-market combines enterprise field sales to healthcare professionals, HCP self-serve portals (GSKPro, GSK Medical), pharmacy network partnerships (Innovicares, Valtrex One), and direct distribution through wholesalers and the Ste-Foy manufacturing site. Customers include physicians, specialists, hospitals, pharmacists, and provincial health authorities, with patient advocacy organizations funded through grants as part of stakeholder engagement.

GSK Canada firmographics

Firmographics
Name
GSK Canada
Legal name
GlaxoSmithKline Inc.
Website
https://ca.gsk.com
Company type
Private
Founded year
1902
Operating status
Operating
Short description
GSK Canada is the wholly-owned Canadian subsidiary of GSK plc, selling specialty medicines, vaccines, and general medicines across oncology, respiratory, HIV, and infectious diseases, generating approximately $1.05 billion in 2024 revenue through prescription and public reimbursement channels.
Ownership category
akta.pro rank

GSK Canada industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAEAE
Travel & Tropical Disease Vaccines

Keywords

  • Prescription pharmaceuticals
  • Vaccine manufacturing
  • Specialty medicines
  • Respiratory therapeutics
  • Oncology biologics

Where GSK Canada is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Markets served

GSK Canada business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales (Vaccines, Specialty Medicines, General Medicines): Primary revenue from sales of prescription medicines, vaccines, and consumer health products across Canada. 2024 GSK in Canada Sales: $1,054,949,000. Total Payments to HCPs and HCOs represent 2.03% of Sales.
  2. Specialty Medicines Sales: Revenue from specialty medicines including oncology products (Blenrep, Jemperli, Ojjaara, Zejula), immunology/respiratory products (Benlysta, Nucala, Exdensur), and Flolan.
  3. Vaccine Sales: Revenue from vaccines including Shingrix, Arexvy (RSV), Boostrix, Bexsero, Cervarix, Engerix-B, FluLaval Tetra, Havrix, Infanrix-Hexa, Menjugate Liquid, Menveo, Priorix, Rotarix, Synflorix, Twinrix, Varilrix, Arepanrix H5N1, Flulaval Tetra, Fluviral, Priorix-Tetra.
  4. General Medicines Sales: Revenue from general medicines including Advair, Anoro Ellipta, Arnuity Ellipta, Avamys, Avodart, Breo Ellipta, Clavulin, Flolan, Flovent, Imitrex, Incruse Ellipta, Jalyn, Lamictal, Malarone, Mepron, Parnate, Paxil, Relenza, Serevent, Trelegy Ellipta, Valtrex, Ventolin, Volibris, and Stiefel dermatology products (Clindoxyl, Stieprox, Stieva-A).

Pricing tiers

ModelBillingPrice
OtherMulti-year contract2024 GSK in Canada Sales of $1,054,949,000 with HCP/HCO payments representing 2.03% of Sales

Go-to-market motion1 record

Distribution channels6 records

GSK Canada product offering

Product offering

Core offering

GSK Canada researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines in Canada across three product pillars: Specialty Medicines (oncology and immunology/respiratory biologics such as Blenrep, Jemperli, Ojjaara, Zejula, Benlysta, Nucala, Exdensur), Vaccines (including adjuvanted vaccines Shingrix and Arexvy, plus paediatric and adult immunizations), and General Medicines (respiratory, dermatology, anti-infective and primary care products including the Ellipta inhaler family, Ventolin, Advair, Valtrex, Malarone, Paxil, and Stiefel dermatology brands). The company supports access via patient support programs, public reimbursement negotiations, and HCP-focused portals, and operates the Ste-Foy Vaccine Production Facility in Quebec that supplies Canada's seasonal and pandemic influenza vaccines.

Product overview

GSK Canada's portfolio is organized across three product categories: Specialty medicines, Vaccines, and General medicines. The Specialty medicines portfolio focuses on oncology and respiratory/immunology, including BLENREP (multiple myeloma), JEMPERLI (endometrial cancer), OJJAARA (myelofibrosis), ZEJULA (ovarian cancer), BENLYSTA (lupus), EXDENSUR (severe asthma), and NUCALA (COPD/severe asthma). The Vaccines portfolio is one of the broadest in the industry and includes SHINGRIX (shingles), AREXVY (RSV), BEXSERO (meningococcal B), BOOSTRIX (Tdap), CERVARIX (HPV), ENGERIX-B, HAVRIX, MENVEO, PRIORIX (MMR), TWINRIX (Hep A/B), VARILRIX, FLULAVAL Tetra, and pediatric vaccines. The General medicines portfolio covers respiratory therapies (ADVAIR, ANORO ELLIPTA, BREO ELLIPTA, FLOVENT, INCRUSE ELLIPTA, SEREVENT, TRELEGY ELLIPTA, VENTOLIN), anti-infectives (CLAVULIN, MALARONE, VALTREX), and additional treatments. The Stiefel Dermatology line (CLINDOXYL, STIEPROX, STIEVA-A) adds specialized dermatology products. GSK Canada's R&D is supported by a Ste-Foy vaccine manufacturing facility in Québec that produces Canada's seasonal influenza vaccine and pandemic influenza vaccine requirements.

Differentiator

Problem solved

Functional benefit

Brands

  • Stiefel: A world-leading specialist dermatology business with innovative products, described as 'Stiefel, a GSK company', offering products like CLINDOXYL, STIEPROX, and STIEVA-A in Canada.
  • ViiV Healthcare

Products and services

  • BENLYSTA (belimumab) A specialty biologic medicine for the treatment of systemic lupus erythematosus (lupus), targeting B-lymphocyte stimulator (BLyS). Supported by the Monarch Patient Support Program.
  • BLENREP (belantamab mafodotin) An antibody-drug conjugate approved in Canada as combination therapy for relapsed/refractory multiple myeloma. Supported by the MyMoment Patient Support Program. pCPA negotiations initiated May 2026.
  • EXDENSUR (depemokimab) A long-acting anti-IL-5 monoclonal antibody approved by Health Canada on June 16, 2026 for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps.
  • JEMPERLI (dostarlimab) A PD-1 inhibitor (anti-PD-1 monoclonal antibody) approved for primary advanced or first recurrent endometrial cancer in combination with chemotherapy. Supported by the Jemperli Patient Support Program. Quebec RAMQ public reimbursement effective February 2026.
  • NUCALA (mepolizumab) An anti-IL-5 monoclonal antibody approved by Health Canada on June 9, 2026 as add-on maintenance treatment for adult patients with COPD, in addition to severe asthma and other indications. Supported by the Vista Patient Support Program.
  • OJJAARA (momelotinib) A JAK1/JAK2/ACVR1 inhibitor approved for myelofibrosis in adults with moderate to severe anemia. First publicly reimbursed in Quebec via RAMQ in November 2025. Supported by the MyMoment Patient Support Program.
  • ZEJULA (niraparib) A PARP inhibitor for the maintenance treatment of ovarian cancer. Supported by the Zejula Patient Support Program.
  • SHINGRIX (Recombinant, AS01B adjuvanted) Herpes Zoster (shingles) vaccine, non-live recombinant and AS01B adjuvanted, for adults 50 years and older.
  • AREXVY (RSV vaccine, recombinant, AS01E adjuvanted) Respiratory Syncytial Virus (RSV) vaccine approved for older adults in Canada and publicly funded through prevention programs for older adults as of September 2025.
  • BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) for protection against meningococcal group B disease.
  • BOOSTRIX Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine for booster vaccination (Tdap), also available as BOOSTRIX-Polio with inactivated poliomyelitis component.
  • CERVARIX Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) for cervical cancer prevention.
  • ENGERIX-B Hepatitis B surface antigen (recombinant) vaccine for hepatitis B prevention.
  • FLULAVAL Tetra Quadrivalent Influenza Vaccine (Split Virion, Inactivated) for seasonal influenza prevention. Shipped annually by GSK Canada from the Ste-Foy manufacturing facility.
  • HAVRIX Hepatitis A virus, inactivated vaccine for hepatitis A prevention.
  • MENVEO Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine for meningococcal disease prevention.
  • PRIORIX Combined measles, mumps and rubella vaccine, live, attenuated (MMR). Also available as PRIORIX-Tetra with varicella.
  • TWINRIX Combined hepatitis A virus (inactivated) and hepatitis B surface antigen (recombinant) vaccine.
  • VARILRIX Varicella Virus Vaccine, live, attenuated (Oka-strain) for chickenpox prevention.
  • ADVAIR (salmeterol, fluticasone propionate) A combination inhaler (ICS/LABA) containing salmeterol and fluticasone propionate for asthma and COPD.
  • ANORO ELLIPTA (umeclidinium and vilanterol) A long-acting dual bronchodilator (LAMA/LABA) inhaler for the maintenance treatment of COPD, delivered via the Ellipta device.
  • BREO ELLIPTA (fluticasone furoate / vilanterol) A once-daily ICS/LABA combination inhaler for asthma and COPD maintenance treatment, delivered via the Ellipta device.
  • FLOVENT (fluticasone propionate) An inhaled corticosteroid for the maintenance treatment of asthma.
  • INCRUSE ELLIPTA (umeclidinium) A long-acting muscarinic antagonist (LAMA) inhaler for the maintenance treatment of COPD, delivered via the Ellipta device.
  • TRELEGY ELLIPTA (fluticasone furoate / umeclidinium / vilanterol) The first single-inhaler triple therapy (ICS/LAMA/LABA) for the maintenance treatment of asthma and COPD, delivered via the Ellipta device.
  • VENTOLIN (salbutamol sulphate) A short-acting beta-agonist (SABA) rescue inhaler for asthma and COPD symptoms, available as Ventolin HFA, Ventolin Diskus, Ventolin Respirator Solution, and Ventolin I.V. Infusion Solution.
  • VALTREX (valacyclovir hydrochloride) An antiviral medication for the treatment of herpes simplex, herpes zoster (shingles), and chickenpox. Supported by the Valtrex One program and Innovicares.
  • MALARONE (atovaquone and proguanil hydrochloride) An antimalarial medication for the prevention and treatment of malaria caused by Plasmodium falciparum.
  • Stiefel Dermatology Portfolio (CLINDOXYL, STIEPROX, STIEVA-A) Stiefel (a GSK company) specialty dermatology products including Clindoxyl (clindamycin/benzoyl peroxide) for acne, Stieprox (ciclopirox olamine) for seborrheic dermatitis and dandruff, and Stieva-A (tretinoin) for acne vulgaris.

Companies that use GSK Canada

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles3 records

GSK Canada technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

GSK Canada partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered flagship, core and minor.

  • Save the Children CanadaflagshipGTM or Marketing PartnerLong-standing partnership supporting emergency preparedness for Indigenous children, families and communities at risk of natural disasters. 11,500+ emergency backpacks assembled since 2016 across Alberta, Saskatchewan, Manitoba, Ontario, and Quebec. Aligned with GSK's global partnership with Save the Children.
  • Canadian Red CrosscoreGTM or Marketing PartnerAd hoc grants provided to support recovery and relief efforts in response to natural disasters, providing support to communities where GSK employees work and live. Funds are used to provide shelter, essential items and comfort to those impacted.
  • Canadian Hospice Palliative Care Association (CHPCA)coreStrategic or Co-development PartnerLong-standing supporter; GSK contributed $100,000 in 2025 to help ensure every Canadian has access to quality hospice palliative care. Over $3 million contributed over the last 20 years to support the hospice palliative care movement in Canada.
  • Health Partners International Canada (HPIC)coreStrategic or Co-development PartnerFunded to improve access to medicine and healthcare to children and families living in vulnerable communities around the world.
  • Second HarvestminorStrategic or Co-development PartnerEnvironmental sustainability partner; supported to reduce carbon emissions from coast to coast in Canada.
  • Les ScientifinesminorStrategic or Co-development PartnerSTEM education partner in Canada, supporting equitable education in science, technology, engineering and math for underrepresented populations.
  • FIRST Robotics CanadaminorStrategic or Co-development PartnerSTEM education partner in Canada, supporting equitable education in science, technology, engineering and math.
  • Quebec Consortium for Drug Development (CQDM)coreStrategic or Co-development PartnerInnovation hub partner; GSK Canada works actively with CQDM to investigate new therapeutic targets as well as disruptive platforms for discovery and development.
  • Innovative Medicines CanadacoreOthersCross-sectoral partner to strengthen and grow the innovation environment in Canada. GSK engages with Innovative Medicines Canada, including adherence to its Code of Ethical Practices and Voluntary Framework on Disclosure of payments to HCPs/HCOs.
  • Canadian Health Policy InstituteminorOthersCross-sectoral partner; works with GSK on strengthening the innovation environment in Canada.
  • Coalition for Action on Innovation in CanadaminorOthersCross-sectoral partner; works with GSK to strengthen the innovation environment in Canada.
  • Conference Board of CanadaminorOthersCross-sectoral partner; works with GSK to strengthen and grow the innovation environment in Canada.
  • pan-Canadian Pharmaceutical Alliance (pCPA)flagshipStrategic or Co-development PartnerNegotiation partner for public reimbursement of GSK products in Canada. Successful negotiations completed for Jemperli (Dec 2025) and Ojjaara (Nov 2025); negotiations initiated for Blenrep (May 2026); letter of intent agreed for Ojjaara (Sep 2025).
  • Dalhousie University (Canadian Center for Vaccinology - CCfV)coreStrategic or Co-development PartnerCollaboration to address health equity gaps through the GSK Vaccinology and Health Equity Fellowship Award, awarded to Dr. Stephana Julia Moss in June 2025.
  • Health Products Stewardship Association (HPSA)minorStrategic or Co-development PartnerGSK Canada supports the Medications and Sharps Return Programs of HPSA, providing patients with safe and convenient methods to dispose health products in an environmentally responsible way.
  • ViiV HealthcareflagshipStrategic or Co-development PartnerGSK majority-owns ViiV Healthcare (with Pfizer and Shionogi as shareholders); ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV, with an ambition to end the HIV epidemic. Luis Morales serves as General Manager, ViiV Healthcare Canada on GSK Canada's leadership team.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

GSK Canada competitors and assessment

Company assessment

Direct peers

  • Pfizer Canada: Pfizer Canada is a direct peer as a major multinational pharmaceutical subsidiary operating in Canada across vaccines, oncology, and primary care. Both compete for pCPA reimbursement, HCP engagement, and specialty medicine market share.
  • Merck Canada (MSD): Merck Canada is a direct peer operating in oncology (Keytruda), vaccines, and specialty medicines in Canada. Both companies compete for hospital and specialty pharmacy channels, pCPA negotiations, and Keytruda directly competes with Jemperli in oncology indications.
  • AstraZeneca Canada: AstraZeneca Canada is a direct peer with overlapping respiratory, oncology, and vaccine franchises. Compete head-to-head in COPD/asthma biologics (e.g., Tezspire vs Nucala/Exdensur) and oncology (Imfinzi/Enhertu vs Jemperli/Blenrep).
  • Novartis Canada: Novartis Canada is a direct peer with overlapping specialty medicine portfolio including oncology, respiratory, and immunology products. Both participate in pCPA negotiations for high-cost specialty therapeutics and have similar Canadian commercial infrastructure.
  • Roche Canada: Roche Canada is a direct peer in oncology, respiratory, and specialty therapeutics. Compete directly in oncology indications with overlapping HER2/PD-L1 targets and have similar patient support program models for specialty drug access.
  • Sanofi Canada: Sanofi Canada is a direct peer with a similar portfolio structure (specialty medicines, vaccines including flu/pediatric, and general medicines). Compete directly in vaccines (Sanofi flu vaccines vs Flulaval) and respiratory (Dupixent vs Nucala/Exdensur).
  • Bristol-Myers Squibb Canada: Bristol-Myers Squibb Canada is a direct peer in oncology and specialty medicines. Compete with GSK's PD-1 inhibitor (Jemperli) through Opdivo and have overlapping interests in multiple myeloma and hematology indications.
  • Johnson & Johnson Innovative Medicine Canada: Janssen (J&J Innovative Medicine) Canada is a direct peer in oncology, immunology, and pulmonary hypertension. Compete directly in multiple myeloma (Darzalex vs Blenrep combinations) and immunology (Tremfya vs Benlysta).
  • AbbVie Canada: AbbVie Canada is a direct peer in immunology, oncology, and specialty therapeutics. Compete with Benlysta (lupus) through Skyrizi/Rinvoq and have overlapping interests in hematology and specialty pharmacy distribution.

Broad incumbents

  • Eli Lilly Canada: Eli Lilly Canada is a broad incumbent peer in pharmaceuticals with an expanding Canadian specialty and primary care portfolio. Compete in diabetes, oncology, and immunology, and participate in pCPA negotiations for high-cost specialty therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights8 records

Customer concentration

GSK Canada social profiles

Digital presence

GSK Canada compliance and trust

Trust signal

Compliance2 records

GSK Canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GSK Canada leadership team

Management profile

Number of profiles

Profiles6 records

GSK Canada subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

GSK Canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GSK Canada M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GSK Canada

What does GSK Canada do?

GSK Canada researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines in Canada across three product pillars: Specialty Medicines (oncology and immunology/respiratory biologics such as Blenrep, Jemperli, Ojjaara, Zejula, Benlysta, Nucala, Exdensur), Vaccines (including adjuvanted vaccines Shingrix and Arexvy, plus paediatric and adult immunizations), and General Medicines (respiratory, dermatology, anti-infective and primary care products including the Ellipta inhaler family, Ventolin, Advair, Valtrex, Malarone, Paxil, and Stiefel dermatology brands). The company supports access via patient support programs, public reimbursement negotiations, and HCP-focused portals, and operates the Ste-Foy Vaccine Production Facility in Quebec that supplies Canada's seasonal and pandemic influenza vaccines.

Is GSK Canada a public or private company?

GSK Canada is a private company. It is classified as corporate owned and is currently operating.

When was GSK Canada founded?

GSK Canada was founded in 1902.

Where is GSK Canada based?

GSK Canada is headquartered in Mississauga, Canada, in the North America region.

How does GSK Canada make money?

Four revenue lines are on record. Pharmaceutical Product Sales (Vaccines, Specialty Medicines, General Medicines) is the primary driver. The others are specialty Medicines Sales, vaccine Sales and general Medicines Sales.

Who are GSK Canada's main competitors?

Direct peers on record are Pfizer Canada, Merck Canada (MSD), AstraZeneca Canada, Novartis Canada, Roche Canada, Sanofi Canada, Bristol-Myers Squibb Canada, Johnson & Johnson Innovative Medicine Canada and AbbVie Canada. Eli Lilly Canada is listed as a broad incumbent.

Does GSK Canada have an API?

No public API is recorded for GSK Canada.

What industry is GSK Canada in?

GSK Canada's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAEAE, Travel & Tropical Disease Vaccines. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireGSK appoints Tina Graves as President & General Manager, CanadaGSK appointed Tina Graves as president and general manager of its Canadian operations on August 26, 2026. Graves will lead specialty medicines, vaccines, and general medicines, with a focus on respiratory, immunology, oncology, HIV, and infectious diseases. She previously served as GSK Taiwan's vice president and general manager.Pharmaceutical TechnologyGSK eyes future growth with cost-cutting plan amid promising Q2 - Pharmaceutical TechnologyGSK has announced a new cost-cutting plan alongside Q2 results, aiming to save £1.9bn ($2.5bn) by 2029 to offset the impact of key drug patent expiries, particularly dolutegravir which faces market exclusivity loss between 2028 and 2030. The British pharma giant reported £8.4bn in total Q2 sales, up 5% year-on-year and above analyst expectations, with specialty medicine sales growing 14% to £3.8bn. As part of its strategic shift toward oncology and specialty medicines, GSK plans to relocate its UK R&D operations from Stevenage to Cambridge with a £400m flagship facility housing over 1,000 scientists.YahooGSK’s ADC prospects brighten further with Hansoh’s second Phase III triumphHansoh Pharma announced a second Phase III success for its B7-H3-targeting ADC risvutatug rezetecan (ris-rez) in osteosarcoma, with the ARTEMIS-011 study showing statistically significant improvement in progression-free survival versus standard chemotherapy. GSK, which licensed ris-rez for up to $1.5 billion in 2023, is conducting the global EMBOLD Sarcoma-202 study as part of its strategy to rebuild its oncology portfolio after exiting the space in 2015. The osteosarcoma win follows an earlier Phase III triumph in small cell lung cancer, positioning ris-rez as a potential contributor to GSK's oncology growth alongside recently approved lung cancer drug Jideytro and multiple myeloma ADC Blenrep.NewswireGSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in CanadaGSK Canada announced approval of Shingrix in a prefilled syringe, simplifying administration by eliminating reconstitution. The new presentation is expected to be available across Canada in early 2027, with the same indications as the existing vial-based product.LinkedInStrides Pharma Sells Majority Stake in Pivot Path to Ascent CapitalPharma and biotech companies are accelerating large acquisitions in 2026, driven by a patent cliff that threatens 200-400 billion dollars in revenue as nearly 200 drugs lose exclusivity by 2030, with companies forced to buy de-risked assets rather than build replacements internally. Three major deals near 10 billion each were completed in under a month—GSK paid 10.6 billion for Nuvalent, AbbVie 10.9 billion for Apogee, and Vertex 10.0 billion for Crinetics—with even financially healthy companies like Vertex now pursuing acquisitions to diversify, signaling a crowded and competitive deal environment. European and UK late-stage biotechs are increasingly attractive targets as the EU's Biotech Act II incentivizes keeping biomanufacturing in Europe.Local BreakingVaccine research, innovation group launches at UW School of PharmacyThe University of Waterloo's School of Pharmacy launched the Pharmacy Innovation and Immunization Research Collaborative on Friday, backed by a $300,000 investment from GSK Canada, to improve vaccine access in underserved communities across Canada. The initiative will address not only vaccine delivery and access barriers but also tackle vaccine misinformation and hesitancy while leveraging the expanded scope of practice that now allows pharmacists to administer more vaccines. Researchers hope the collaborative will help better prepare Canada for future disease outbreaks.University of Waterloo$300,000 GSK Canada grant supports PIIRC initiatives to advance vaccine access, delivery and educationGSK Canada provided a $300,000 grant to the University of Waterloo School of Pharmacy to support the launch of the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) initiative. The funding aims to enhance vaccine access, delivery, and education, with a focus on training pharmacists and implementing technology solutions across Canada.PR NewswireLos Angeles Comes Together to Be Powerful and Walk to End Lupus NowThe Lupus Foundation of America will host its annual Walk to End Lupus Now event in Los Angeles on September 28, 2019, at LA Live, with actress Kate Linder serving as Grand Marshal and actor Ian Harding as a special guest. The event, themed "Be Powerful," aims to raise funds for lupus research and increase awareness of the disease, which affects an estimated 1.5 million Americans and five million people worldwide. GSK is a sponsor of the event, and POWER 106 FM is the media partner.